Editorial: Identification of novel biomarkers for pancreatic and hepatocellular cancers.

Therefore, in the last years there has been an increasing trend toward neoadjuvant chemotherapy (NAC) for resectable and borderline resectable disease, in order to control possible micrometastases and select patients with potential benefit from radical resection ( Oba et al. ).

also in 63,971 other papers